mineralys — News — Boulder Ventures Ltd.

Mineralys Therapeutics Announces $120 Million Private Placement Financing

RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD”) and other diseases driven by abnormally elevated aldosterone, today announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting estimated fees and expenses.

Matt PaulFebruary 8, 2024mineralys

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

RADNOR, Pa., Sept. 10, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced that full results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and treatment-resistant hypertension (rHTN) were published in the Journal of the American Medical Association (JAMA)

Matt PaulSeptember 11, 2023mineralys

Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

RADNOR, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced financial results for the quarter ending June 30, 2023, and provided a corporate update.

Matt PaulAugust 7, 2023mineralys

Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at an initial public offering price of $16.00 per share.

Matt PaulFebruary 9, 2023mineralys

After hypertension competitor gets bought, Mineralys lines up IPO plans

Mineralys Therapeutics has penciled in a $100 million initial public offering to take its investigational hypertension drug into Phase III testing.

The Philadelphia startup released topline results for its hypertension drug, dubbed MLS-101 or lorundrostat, two months ago, saying it met the primary endpoint of reducing systolic blood pressure for patients who were on at least two background medicines.

Matt PaulJanuary 22, 2023mineralys

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

PHILADELPHIA, Nov. 16, 2022 /PRNewswire/ -- Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a novel therapy for the treatment of hypertension and associated cardiovascular diseases, today announced topline results from the Phase 2 Target-HTN trial in individuals with uncontrolled and resistant hypertension. MLS-101, a highly selective investigational aldosterone synthase inhibitor, at doses of 50 mg and 100 mg once daily (QD), met its primary endpoint with statistically significant and clinically meaningful reduction in systolic blood pressure (SBP) in inadequately controlled hypertensive patients on at least two background antihypertensive medications.

Matt PaulNovember 16, 2022mineralys

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

PHILADELPHIA, June 8, 2022 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension, today announced the completion of an oversubscribed and up-sized $118 million Series B financing.

Matt PaulJune 8, 2022mineralys